Representative Matter

Related Content

Practices
Industries
Professionals

Fortune 500 pharmaceutical company

Representation of a Fortune 500 pharmaceutical company in connection with its acquisition of a diagnostic substance and chemical manufacturer, pursuant to a reverse triangular merger. Total consideration was approximately $135 million.